Biomarker identification in the realm of rare diseases
Drug Target Review
MAY 7, 2024
For instance, AI algorithms could facilitate patient-trial matching, encompassing medical records, genetic information, demographics, and personal preferences. At Debiopharm, he has overseen both preclinical and clinical pharmacology of assets from phase I to III.
Let's personalize your content